Echelon Biosciences, Inc (EBI) was founded as Echelon Research Labs by two professors from the University of Utah.  Their initial goal was to advance the science of lipid signaling by developing novel research reagents, assays, and ultimately technology leading to drug treatments and diagnostics for debilitating diseases.

Our Vision

Elevating science to enable a healthier world.

Our Mission

Moving science forward with unique products and an adventurous spirit.

Our Commitment

We aim to conduct science that benefits both people and our planet.

Management Team

Dr. Neilsen was a Y-Scholar at Brigham Young University, earning a B.S. in Biochemistry from BYU then a Ph.D. in Experimental Pathology from the University of Utah. He has more than 20 years of diverse research experience in phosphoinositides, drug discovery/assay development, and clinical biomarker development. As R&D director, he has led groups responsible for the discovery, development, and release of hundreds of innovative biochemical products. Dr. Neilsen is a co-inventor on several patents, co-author on numerous publications, and has received multiple grants & contracts from three separate NIH Institutes and DoD.
Dr. Ferguson has a B.S. with honors in Chemistry and Oceanography from the University of British Columbia and a Ph.D. in Chemistry from Queens University. He was a Postdoctoral Associate with Prof. Glenn D. Prestwich at the University of Utah focusing on phosphoinositide and phospholipid synthesis. Dr. Ferguson has been with Echelon since 2001 where his experience in phospholipid chemistry allows Echelon to expand its product offerings and constantly improve its operational efficiencies.
Ms. Sauder has been with Echelon Biosciences since 2005. Ms. Sauder has many years of experience in public accounting and auditing in the private business sector. She has Bachelor’s of Science degrees in both Accounting and Business Economics. Ms. Sauder administers all accounting and human resources functions at Echelon and also aides in materials procurement, inventory management, and bulk quotation.

1997

Founding

Echelon Research Labs established as a university spin-out from the University of Utah

1997

2003

New Spaces

Move into new headquarters and rebrand as Echelon Biosciences

2003

2004

Aeterna Zentaris

Echelon is purchased by the German-Canadian pharmaceutical company Aeterna-Zentaris on the strength of their assay development

2004

2007

Back to Utah

Echelon is acquired by Frontier Scientific, now Frontier Specialty Chemicals, bringing them back as a Utah-based company

2007

2014

Peptide acquisition

Echelon purchases California Peptide to expand catalog offerings and synthesis capabilities

2014

2020

Around the world

Expansion of worldwide distributor network to include markets in South and Southeast Asia

2020

2021

New Partners

Continuing to grow by partnering with HTL Biotechnology and Gulliver Biomed to expand product offerings in Hyaluronic Acid and Nanobody Production

2021

Present Day

Future Horizons

We continue to work towards solutions in all research spaces as we look to new areas where we can contribute our expertise

Present Day
Shopping Cart
Scroll to Top